|
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
|
24 April 2017 |
|
Novartis expands development programs for NASH through clinical collaboration with Allergan
|
18 April 2017 |
|
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
|
07 April 2017 |
|
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
|
22 March 2017 |
|
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
|
20 March 2017 |
|
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
|
13 March 2017 |
|
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
|
07 March 2017 |
|
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
|
23 February 2017 |
|
Novartis delivered solid 2016 performance
|
25 January 2017 |
|
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
|
06 January 2017 |